Bromide

Bromide

SCHEMBL2528600

Br.COc1ccc(C)cc1C(CCN(C(C)C)C(C)C)c1ccccc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 3/20 0.67
CHRM3 known ✓ P20309 2/20 0.67
SLC6A4 known ✓ P31645 1/20 0.67
ADRA1A known ✓ P35348 1/20 0.67
ADRB2 known ✓ P07550 1/20 0.58
SIGMAR1 known ✓ Q99720 1/20 0.58
CHRM1 P11229 3/20 0.67
HRH1 P35367 3/20 0.67
MAPT P10636 3/20 0.67
CHRM5 P08912 2/20 0.67
HTR2A P28223 2/20 0.67
LMNA P02545 1/20 0.67
ESR1 P03372 1/20 0.67
CHRM4 P08173 1/20 0.67
KCNE1 P15382 1/20 0.67
PTGS1 P23219 1/20 0.67
HRH2 P25021 1/20 0.67
OPRK1 P41145 1/20 0.67
KCNQ1 P51787 1/20 0.67
KCNH2 Q12809 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2528597 1.00 CHRM2 (0.67) CHRM2CHRM1HRH1MAPTCHRM5
SCHEMBL614300 0.99 CHRM2 (0.68) CHRM2CHRM1HRH1MAPTCHRM5
SCHEMBL2522817 0.99 CHRM2 (0.68) CHRM2CHRM1HRH1MAPTCHRM5
Hydrochloric Acid SCHEMBL615546 0.97 CHRM2 (0.67) CHRM2CHRM1HRH1MAPTCHRM5
Fumaric Acid SCHEMBL1261697 0.90 CHRM2 (0.61) CHRM2CHRM1HRH1MAPTCHRM5
Fumaric Acid SCHEMBL1261695 0.90 CHRM2 (0.61) CHRM2CHRM1HRH1MAPTCHRM5
Cadaverine Tartrate SCHEMBL2528604 0.90 CHRM2 (0.74) CHRM2CHRM1HRH1MAPTCHRM5
Cadaverine Tartrate SCHEMBL2528602 0.90 CHRM2 (0.74) CHRM2CHRM1HRH1MAPTCHRM5
SCHEMBL9227827 0.90 MAPT (0.55) CHRM2CHRM1HRH1MAPTCHRM5
SCHEMBL9228278 0.89 CHRM2 (0.53) CHRM2CHRM1HRH1MAPTCHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039672-B2 Method of obtaining 3,3-diphenylpropylamines INTERQUIM, S.A. (ES) 2011-10-18 US claimed
US-20100286446-A1 Method of Obtaining 3,3-Diphenylpropylamines INTERQUIM, S.A. (ES) 2010-11-11 US claimed
US-7473805-B2 Process for obtaining tolterodine RAGACTIVES, S.L. PARQUE TECNOLOGICO DE BOECILLO (ES) 2009-01-06 US claimed
EP-1927585-A2 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES Ragactives, S.L. (ES) 2008-06-04 EP claimed
US-20070254959-A1 Process for Obtaining Tolterodine RAGACTIVES, S.L. (ES) 2007-11-01 US claimed
EP-1698615-B1 METHOD OF OBTAINING TOLTERODINE RAGACTIVES SL (ES) 2007-10-31 EP claimed
EP-1698615-A1 METHOD OF OBTAINING TOLTERODINE Ragactives, S.L. (ES) 2006-09-06 EP claimed
US-20110319666-A1 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES BONDE-LARSEN ANTONIO LORENTE (ES) 2011-12-29 US disclosed
US-8039672-B2 Method of obtaining 3,3-diphenylpropylamines INTERQUIM, S.A. (ES) 2011-10-18 US disclosed
US-20100286446-A1 Method of Obtaining 3,3-Diphenylpropylamines INTERQUIM, S.A. (ES) 2010-11-11 US disclosed
US-7473805-B2 Process for obtaining tolterodine RAGACTIVES, S.L. PARQUE TECNOLOGICO DE BOECILLO (ES) 2009-01-06 US disclosed
EP-1927585-A2 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES Ragactives, S.L. (ES) 2008-06-04 EP disclosed
US-20070254959-A1 Process for Obtaining Tolterodine RAGACTIVES, S.L. (ES) 2007-11-01 US disclosed
EP-1698615-B1 METHOD OF OBTAINING TOLTERODINE RAGACTIVES SL (ES) 2007-10-31 EP disclosed
EP-1698615-A1 METHOD OF OBTAINING TOLTERODINE Ragactives, S.L. (ES) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254959-A1 Process for Obtaining Tolterodine ADRB2, ADRB3, ADRB1 CHRM2 19/4885CHRM3 14/4885SLC6A4 370/4885
US-20110319666-A1 METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES CHRM3, CNR2, CHRM2 CHRM2 3/4885CHRM3 1/4885SLC6A4 113/4885
US-20100286446-A1 Method of Obtaining 3,3-Diphenylpropylamines CHRM3, HRH4, ADRB3 CHRM2 4/4885CHRM3 1/4885SLC6A4 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.